ELIEM THERAPEUTICS INC (ELYM)

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Name change to

Eliem Therapeutics Enters Oversold Territory (ELYM)

Eliem Therapeutics (ELYM) Shares Cross Below 200 DMA

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the...

Eliem Therapeutics Announces Additions to its Leadership Team

Eliem Therapeutics Announces Additions to its Leadership Team

Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE,...

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q2 2024

Eliem Therapeutics just reported results for the second quarter of 2024.

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eliem Therapeutics (NASDAQ:ELYM) just reported results for the second quarter o...

Eliem Therapeutics Reports Second Quarter Financial Results

Eliem Therapeutics Reports Second Quarter Financial Results

Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to...

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will...

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus,...

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q1 2024

Eliem Therapeutics just reported results for the first quarter of 2024.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm

/PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders....

Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Thursday Sector Leaders: Drugs, Shipping Stocks

ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have...

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023

Eliem Therapeutics just reported results for the fourth quarter of 2023.

ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eliem Therapeutics (NASDAQ:ELYM) just reported results for the fourth quarter o...